Karadsheh Zeid, Sule Sachin
Department of Medicine, Brockton Hospital, Brockton, Massachusetts, USA.
N Am J Med Sci. 2013 Jun;5(6):339-43. doi: 10.4103/1947-2714.114163.
Clostridium difficile infection (CDI) is currently a leading cause of antibiotic and health care-related diarrhea. The incidence and the severity of CDI-related diarrhea have increased dramatically in the USA and Europe in the past few decades. The emergence of multidrug-resistant hypervirulent strains of C. difficile has led to an increase in mortality. Fecal microbiota transplantation (FMT) (also known as fecal bacteriotherapy) has been utilized sporadically since the 1950s; and currently, the interest in using FMT has grown again in the past few years for the treatment of CDI and other chronic gastrointestinal diseases. FMT has shown to be effective, cheap, and has very few side effects. It is believed to manipulate and restore the gut microbiota, and therefore enhances the growth of "healthy" bacteria that break the cycle of recurrent CDI. This article focus on the recent case reports on FMT, and general approach to patients undergoing this therapy. Data were obtained through a literature search via PubMed and Google.
艰难梭菌感染(CDI)目前是抗生素相关性腹泻和医疗保健相关性腹泻的主要病因。在过去几十年中,美国和欧洲与CDI相关腹泻的发病率和严重程度急剧上升。艰难梭菌多重耐药高毒力菌株的出现导致死亡率增加。自20世纪50年代以来,粪便微生物群移植(FMT)(也称为粪便细菌疗法)就一直被零星使用;目前,在过去几年中,人们对使用FMT治疗CDI和其他慢性胃肠疾病的兴趣再度高涨。FMT已被证明是有效、廉价且副作用极少的。据信,它可以操纵和恢复肠道微生物群,从而促进“健康”细菌的生长,打破复发性CDI的循环。本文重点关注FMT的近期病例报告以及接受该疗法患者的一般治疗方法。数据通过PubMed和谷歌进行文献检索获得。